Christopher J Collins1, Fan Yi1, Remwilyn Dayuha1, Phi Duong1, Simon Horslen2, Michelle Camarata3, Ayse K Coskun3, Roderick H J Houwen4, Tudor L Pop5, Heinz Zoller6, Han-Wook Yoo7, Sung Won Jung8, Karl H Weiss9, Michael L Schilsky3, Peter Ferenci10, Si Houn Hahn11. 1. Seattle Children's Research Institute, Seattle, Washington. 2. University of Washington School of Medicine, Seattle, Washington. 3. Yale University School of Medicine, New Haven, Connecticut. 4. Wilhelmina Children's Hospital, University Medical Center, Utrecht, The Netherlands. 5. Second Pediatric Clinic, University of Medicine and Pharmacy, Iuliu Hatieganu, Cluj-Napoca, Romania. 6. Medical University of Innsbruck, Innsbruck, Austria. 7. Asan Medical Center, Seoul, Korea. 8. Gachon University School of Medicine, Incheon, Korea. 9. Heidelberg University Hospital, Heidelberg, Germany. 10. Medical University of Vienna, Vienna, Austria. Electronic address: peter.ferenci@meduniwien.ac.at. 11. Seattle Children's Research Institute, Seattle, Washington; University of Washington School of Medicine, Seattle, Washington. Electronic address: sihahn@uw.edu.
Abstract
BACKGROUND & AIMS: Both existing clinical criteria and genetic testing have significant limitations for the diagnosis of Wilson disease (WD), often creating ambiguities in patient identification and leading to delayed diagnosis and ineffective management. ATP7B protein concentration, indicated by direct measurement of surrogate peptides from patient dried blood spot samples, could provide primary evidence of WD. ATP7B concentrations were measured in patient samples from diverse backgrounds, diagnostic potential is determined, and results are compared with biochemical and genetic results from individual patients. METHODS: Two hundred and sixty-four samples from biorepositories at 3 international and 2 domestic academic centers and 150 normal controls were obtained after Institutional Review Board approval. Genetically or clinically confirmed WD patients with a Leipzig score >3 and obligate heterozygote (carriers) from affected family members were included. ATP7B peptide measurements were made by immunoaffinity enrichment mass spectrometry. RESULTS: Two ATP7B peptides were used to measure ATP7B protein concentration. Receiver operating characteristics curve analysis generates an area under the curve of 0.98. ATP7B peptide analysis of the sequence ATP7B 887 was found to have a sensitivity of 91.2%, specificity of 98.1%, positive predictive value of 98.0%, and a negative predictive value of 91.5%. In patients with normal ceruloplasmin concentrations (>20 mg/dL), 14 of 16 (87.5%) were ATP7B-deficient. In patients without clear genetic results, 94% were ATP7B-deficient. CONCLUSIONS: Quantification of ATP7B peptide effectively identified WD patients in 92.1% of presented cases and reduced ambiguities resulting from ceruloplasmin and genetic analysis. Clarity is brought to patients with ambiguous genetic results, significantly aiding in noninvasive diagnosis. A proposed diagnostic score and algorithm incorporating ATP7B peptide concentrations can be rapidly diagnostic and supplemental to current Leipzig scoring systems.
BACKGROUND & AIMS: Both existing clinical criteria and genetic testing have significant limitations for the diagnosis of Wilson disease (WD), often creating ambiguities in patient identification and leading to delayed diagnosis and ineffective management. ATP7B protein concentration, indicated by direct measurement of surrogate peptides from patient dried blood spot samples, could provide primary evidence of WD. ATP7B concentrations were measured in patient samples from diverse backgrounds, diagnostic potential is determined, and results are compared with biochemical and genetic results from individual patients. METHODS: Two hundred and sixty-four samples from biorepositories at 3 international and 2 domestic academic centers and 150 normal controls were obtained after Institutional Review Board approval. Genetically or clinically confirmed WD patients with a Leipzig score >3 and obligate heterozygote (carriers) from affected family members were included. ATP7B peptide measurements were made by immunoaffinity enrichment mass spectrometry. RESULTS: Two ATP7B peptides were used to measure ATP7B protein concentration. Receiver operating characteristics curve analysis generates an area under the curve of 0.98. ATP7B peptide analysis of the sequence ATP7B 887 was found to have a sensitivity of 91.2%, specificity of 98.1%, positive predictive value of 98.0%, and a negative predictive value of 91.5%. In patients with normal ceruloplasmin concentrations (>20 mg/dL), 14 of 16 (87.5%) were ATP7B-deficient. In patients without clear genetic results, 94% were ATP7B-deficient. CONCLUSIONS: Quantification of ATP7B peptide effectively identified WD patients in 92.1% of presented cases and reduced ambiguities resulting from ceruloplasmin and genetic analysis. Clarity is brought to patients with ambiguous genetic results, significantly aiding in noninvasive diagnosis. A proposed diagnostic score and algorithm incorporating ATP7B peptide concentrations can be rapidly diagnostic and supplemental to current Leipzig scoring systems.
Authors: Eric Kuhn; Jeffrey R Whiteaker; D R Mani; Angela M Jackson; Lei Zhao; Matthew E Pope; Derek Smith; Keith D Rivera; N Leigh Anderson; Steven J Skates; Terry W Pearson; Amanda G Paulovich; Steven A Carr Journal: Mol Cell Proteomics Date: 2011-12-22 Impact factor: 5.911
Authors: Brendan MacLean; Daniela M Tomazela; Nicholas Shulman; Matthew Chambers; Gregory L Finney; Barbara Frewen; Randall Kern; David L Tabb; Daniel C Liebler; Michael J MacCoss Journal: Bioinformatics Date: 2010-02-09 Impact factor: 6.937
Authors: Peter Ferenci; Wolfgang Stremmel; Anna Członkowska; Ferenc Szalay; André Viveiros; Albert Friedrich Stättermayer; Radan Bruha; Roderick Houwen; Tudor Lucian Pop; Rudolf Stauber; Michael Gschwantler; Jan Pfeiffenberger; Cihan Yurdaydin; Elmar Aigner; Petra Steindl-Munda; Hans-Peter Dienes; Heinz Zoller; Karl Heinz Weiss Journal: Hepatology Date: 2019-03-01 Impact factor: 17.425
Authors: Sunhee Jung; Jeffrey R Whiteaker; Lei Zhao; Han-Wook Yoo; Amanda G Paulovich; Si Houn Hahn Journal: J Proteome Res Date: 2016-12-09 Impact factor: 4.466
Authors: Albert Friedrich Stättermayer; Andreas Entenmann; Michael Gschwantler; Heinz Zoller; Harald Hofer; Peter Ferenci Journal: Eur J Clin Invest Date: 2019-06-20 Impact factor: 4.686
Authors: Christopher J Collins; Fan Yi; Remwilyn Dayuha; Jeffrey R Whiteaker; Hans D Ochs; Alexandra Freeman; Helen C Su; Amanda G Paulovich; Gesmar R S Segundo; Troy Torgerson; Si Houn Hahn Journal: Front Immunol Date: 2020-04-01 Impact factor: 7.561
Authors: Abolfazl Avan; Anna Członkowska; Susan Gaskin; Alberto Granzotto; Stefano L Sensi; Tjaard U Hoogenraad Journal: Int J Mol Sci Date: 2022-08-18 Impact factor: 6.208
Authors: Marlene Panzer; André Viveiros; Benedikt Schaefer; Nadja Baumgartner; Klaus Seppi; Atbin Djamshidian; Theodor Todorov; William J H Griffiths; Eckart Schott; Markus Schuelke; Dennis Eurich; Albert Friedrich Stättermayer; Adrian Bomford; Pierre Foskett; Julia Vodopiutz; Rudolf Stauber; Elke Pertler; Bernhard Morell; Herbert Tilg; Thomas Müller; Stefan Kiechl; Raul Jimenez-Heredia; Karl Heinz Weiss; Si Houn Hahn; Andreas Janecke; Peter Ferenci; Heinz Zoller Journal: Hepatol Commun Date: 2022-03-10